AAAAAA

   
Results: 1-11 |
Results: 11
CHOOSING DRUG-THERAPY FOR MULTIPLE-SCLEROSIS - AN UPDATE
Authors: VANOOSTEN BW TRUYEN L BARKHOF F POLMAN CH
Citation: Bw. Vanoosten et al., CHOOSING DRUG-THERAPY FOR MULTIPLE-SCLEROSIS - AN UPDATE, Drugs, 56(4), 1998, pp. 555-569
INCREASED PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA, AND NOT OF INTERFERON-GAMMA, PRECEDING DISEASE-ACTIVITY IN PATIENTS WITH MULTIPLE-SCLEROSIS
Authors: VANOOSTEN BW BARKHOF F SCHOLTEN PET VONBLOMBERG ME ADER HJ POLMAN CH
Citation: Bw. Vanoosten et al., INCREASED PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA, AND NOT OF INTERFERON-GAMMA, PRECEDING DISEASE-ACTIVITY IN PATIENTS WITH MULTIPLE-SCLEROSIS, Archives of neurology, 55(6), 1998, pp. 793-798
TNF-ALPHA PROMOTER POLYMORPHISMS, PRODUCTION AND SUSCEPTIBILITY TO MULTIPLE-SCLEROSIS IN DIFFERENT GROUPS OF PATIENTS
Authors: HUIZINGA TWJ WESTENDORP RGJ BOLLEN ELEM KEIJSERS V BRINKMAN BMN LANGERMANS JAM BREEDVELD FC VERWEIJ CL VANDEGAER L DAMS L CRUSIUS JBA GARCIAGONZALEZ A VANOOSTEN BW POLMAN CH PENA AS
Citation: Twj. Huizinga et al., TNF-ALPHA PROMOTER POLYMORPHISMS, PRODUCTION AND SUSCEPTIBILITY TO MULTIPLE-SCLEROSIS IN DIFFERENT GROUPS OF PATIENTS, Journal of neuroimmunology, 72(2), 1997, pp. 149-153
TREATMENT OF MULTIPLE-SCLEROSIS WITH THE MONOCLONAL ANTI-CD4 ANTIBODYCM-T412 - RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MR-MONITORED PHASE-II TRIAL
Authors: VANOOSTEN BW LAI M HODGKINSON S BARKHOF F MILLER DH MOSELEY IF THOMPSON AJ RUDGE P MCDOUGALL A MCLEOD JG ADER HJ POLMAN CH
Citation: Bw. Vanoosten et al., TREATMENT OF MULTIPLE-SCLEROSIS WITH THE MONOCLONAL ANTI-CD4 ANTIBODYCM-T412 - RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MR-MONITORED PHASE-II TRIAL, Neurology, 49(2), 1997, pp. 351-357
INTERLEUKIN-2 THERAPY DOES NOT EXACERBATE MULTIPLE-SCLEROSIS
Authors: VANOOSTEN BW UITDEHAAG BMJ BARKHOF F HARTUNG HP WAGSTAFF J POLMAN CH
Citation: Bw. Vanoosten et al., INTERLEUKIN-2 THERAPY DOES NOT EXACERBATE MULTIPLE-SCLEROSIS, Neurology, 49(2), 1997, pp. 633-634
TREATMENT WITH DEPLETING CD4 MONOCLONAL-ANTIBODY RESULTS IN A PREFERENTIAL LOSS OF CIRCULATING NAIVE T-CELLS BUT DOES NOT AFFECT IFN-GAMMA SECRETING TH1 CELLS IN HUMANS
Authors: REP MHG VANOOSTEN BW ROOS MTL ADER HJ POLMAN CH VANLIER RAW
Citation: Mhg. Rep et al., TREATMENT WITH DEPLETING CD4 MONOCLONAL-ANTIBODY RESULTS IN A PREFERENTIAL LOSS OF CIRCULATING NAIVE T-CELLS BUT DOES NOT AFFECT IFN-GAMMA SECRETING TH1 CELLS IN HUMANS, The Journal of clinical investigation, 99(9), 1997, pp. 2225-2231
A PILOT-STUDY INVESTIGATING THE EFFECTS OF ORALLY-ADMINISTERED PENTOXIFYLLINE ON SELECTED IMMUNE VARIABLES IN PATIENTS WITH MULTIPLE-SCLEROSIS
Authors: VANOOSTEN BW REP MHG VANLIER RAW SCHOLTEN PET VONBLOMBERG BME PFLUGHAUPT KW HARTUNG HP ADER HJ POLMAN CH
Citation: Bw. Vanoosten et al., A PILOT-STUDY INVESTIGATING THE EFFECTS OF ORALLY-ADMINISTERED PENTOXIFYLLINE ON SELECTED IMMUNE VARIABLES IN PATIENTS WITH MULTIPLE-SCLEROSIS, Journal of neuroimmunology, 66(1-2), 1996, pp. 49-55
ACCUMULATION OF HYPOINTENSE LESIONS (BLACK-HOLES) ON T-1 SPIN-ECHO MRI CORRELATES WITH DISEASE PROGRESSION IN MULTIPLE-SCLEROSIS
Authors: TRUYEN L VANWAESBERGHE JHTM VANWALDERVEEN MAA VANOOSTEN BW POLMAN CH HOMMES OR ADER HJA BARKHOF F
Citation: L. Truyen et al., ACCUMULATION OF HYPOINTENSE LESIONS (BLACK-HOLES) ON T-1 SPIN-ECHO MRI CORRELATES WITH DISEASE PROGRESSION IN MULTIPLE-SCLEROSIS, Neurology, 47(6), 1996, pp. 1469-1476
INCREASED MRI ACTIVITY AND IMMUNE ACTIVATION IN 2 MULTIPLE-SCLEROSIS PATIENTS TREATED WITH THE MONOCLONAL ANTITUMOR NECROSIS FACTOR ANTIBODY CA2
Authors: VANOOSTEN BW BARKHOF F TRUYEN L BORINGA JB BERTELSMANN FW VONBLOMBERG BME WOODY JN HARTUNG HP POLMAN CH
Citation: Bw. Vanoosten et al., INCREASED MRI ACTIVITY AND IMMUNE ACTIVATION IN 2 MULTIPLE-SCLEROSIS PATIENTS TREATED WITH THE MONOCLONAL ANTITUMOR NECROSIS FACTOR ANTIBODY CA2, Neurology, 47(6), 1996, pp. 1531-1534
INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM AND MULTIPLE-SCLEROSIS
Authors: CRUSIUS JBA PENA AS VANOOSTEN BW BIOQUE G GARCIA A DIJKSTRA CD POLMAN CH
Citation: Jba. Crusius et al., INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM AND MULTIPLE-SCLEROSIS, Lancet, 346(8980), 1995, pp. 979-980
MULTIPLE-SCLEROSIS THERAPY - A PRACTICAL GUIDE
Authors: VANOOSTEN BW TRUYEN L BARKHOF F POLMAN CH
Citation: Bw. Vanoosten et al., MULTIPLE-SCLEROSIS THERAPY - A PRACTICAL GUIDE, Drugs, 49(2), 1995, pp. 200-212
Risultati: 1-11 |